会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 34. 发明授权
    • Method for generating aptamers with improved off-rates
    • 用于产生具有改善的脱离率的适配体的方法
    • US07964356B2
    • 2011-06-21
    • US12499967
    • 2009-07-09
    • Dominic ZichiSheri K. WilcoxChris BockDaniel J. SchneiderBruce EatonLarry Gold
    • Dominic ZichiSheri K. WilcoxChris BockDaniel J. SchneiderBruce EatonLarry Gold
    • C12Q1/68C07H21/02
    • C12N15/1048C12Q1/6811C12Q2525/205
    • The present disclosure describes methods for producing aptamers and photoaptamers having slower dissociation rate constants than are obtained using prior SELEX and photoSELEX methods. The disclosure further describes aptamers and photoaptamers having slower dissociation rate constants than those obtained using prior methods. This invention relates to the field of diagnostic histology, cytology, histopathology, and cytopathology methods and reagents for the detection of various disease states. More specifically, the invention relates to the use of aptamers in histologic, cytologic, histopathic, and/or cytopathic diagnostic methods. Aptamers may be provided that react with specific target molecules contained within a histological or cytological sample. Aptamers may be used to assess localization, relative density, and presence or absence of one or more target. Targets may be selected that are specific and diagnostic of a given disease state for which the sample was collected. Aptamers may be used to introduce target specific signal moieties. Antigen retrieval methods may be applied to the sample prior to reaction with the specific aptamer/s to improve interaction of the aptamer and target within the sample. Or aptamers may be developed for the specific target that eliminates the need for the antigen retrieval process. In addition to target identification, aptamers may be used to amplify signal generation through a variety of methods.
    • 本公开描述了用于产生具有比使用先前的SELEX和photoSELEX方法获得的解离速率常数更慢的适体和光催化剂的方法。 本公开进一步描述了具有比使用现有方法获得的那些更快的解离速率常数的适体和光致抗体。 本发明涉及用于检测各种疾病状态的诊断组织学,细胞学,组织病理学和细胞病理学方法和试剂领域。 更具体地,本发明涉及适配体在组织学,细胞学,组织病理学和/或细胞病变诊断方法中的用途。 可以提供与包含在组织学或细胞学样品中的特定靶分子反应的适配子。 可以使用适配器来评估定位,相对密度以及一个或多个靶的存在或不存在。 可以选择对于样品收集的给定疾病状态的特异性和诊断性的靶标。 适配子可用于引入目标特异性信号部分。 抗原检索方法可以在与特异性适体反应之前应用于样品,以改善样品中适体和靶标的相互作用。 或者可以针对特定靶标开发适配体,从而消除对抗原检索过程的需要。 除目标识别之外,适体可用于通过各种方法放大信号产生。
    • 36. 发明申请
    • Drag reducing agent and method of use
    • 减阻剂和使用方法
    • US20110105642A1
    • 2011-05-05
    • US12589818
    • 2009-10-29
    • Gerald Bruce EatonAlan Kim Ebert
    • Gerald Bruce EatonAlan Kim Ebert
    • B05D5/08
    • F17D1/17
    • The present invention relates to a drag reducing agent, composition, compound, product, process and method of use for use in petroleum pipelines and the like. A preferred embodiment of the present invention provides a cryogenically-ground polyalphaolefin polymer at 15-25 wt. % of the commercial product formulation. The bulking agents comprise ethylene bis-stearamide alone or in combination with other polyethylene and/or polypropylene polymers at 2.0-5.0 wt. % of the commercial product formulation. In addition, diisobutyl ketone 20-60 wt. % of the commercial product formulation and propylene carbonate 2.8-8.4 wt. % of the commercial product formulation are used.
    • 本发明涉及用于石油管道等的减阻剂,组成物,化合物,产品,方法和使用方法。 本发明的优选实施方案提供了15-25重量%的低温法研磨的聚α-烯烃聚合物。 %的商业产品配方。 填充剂单独使用乙烯双硬脂酰胺,或与其它聚乙烯和/或聚丙烯聚合物组合使用,2.0-5.0wt。 %的商业产品配方。 另外,二异丁酮20-60wt。 %的市售产品配方和碳酸丙烯酯2.8-8.4wt。 使用商业产品制剂的%。
    • 39. 发明授权
    • Urea nucleosides as therapeutic and diagnostic agents
    • 尿素核苷作为治疗和诊断剂
    • US06914138B2
    • 2005-07-05
    • US10216553
    • 2002-08-09
    • Gary KirschenheuterBruce Eaton
    • Gary KirschenheuterBruce Eaton
    • C07H11/02C07H19/06C07H19/16C07H19/00C07H19/22
    • C07H11/02C07H19/06C07H19/16
    • Modified nucleosides and methods of making and using the nucleosides are disclosed. The compounds can be prepared by reacting nucleoside starting materials that contain a suitable leaving group at one or more of the carbon atoms in the purine or pyrimidine ring, with a vinylstannane, carbon monoxide, and a palladium catalyst to provide 1-ene-3-one intermediates. These intermediates are then reacted with suitably functionalized primary or secondary amines via a Michael reaction. When the intermediate is a 5-position modified pyrimidine ring, and the amine contains a second hydrogen, it can do a second Michael reaction with the ene-one or the ene-imine in the pyrimidine ring. Appropriate modification of the amine reactant can yield products with various bioactivities. The nucleosides can be used therapeutically as anti-cancer, anti-bacterial or anti-viral drugs. The nucleosides can also be used for diagnostic applications, for example, by incorporating a radiolabel or fluorescent label into the molecule. The nucleosides can be used to prepare oligonucleotides for use in various applications, either alone or in combination with other modified nucleosides and/or naturally occurring nucleosides.
    • 公开了修饰的核苷和制备和使用核苷的方法。 可以通过使含有嘌呤或嘧啶环中的一个或多个碳原子上的合适的离去基团的核苷起始原料与乙烯基苯烷,一氧化碳和钯催化剂反应来制备化合物,以提供1-烯-3-醇, 一个中间体。 然后通过迈克尔反应将这些中间体与适当官能化的伯胺或仲胺反应。 当中间体是5-位修饰的嘧啶环,并且胺含有第二个氢时,它可以与嘧啶环中的一个或烯 - 亚胺进行第二个迈克尔反应。 胺反应物的适当改性可产生具有各种生物活性的产物。 核苷可以用作治疗性的抗癌,抗细菌或抗病毒药物。 核苷也可用于诊断应用,例如通过在分子中掺入放射性标记或荧光标记。 核苷可用于制备用于各种应用的寡核苷酸,单独使用或与其它修饰的核苷和/或天然存在的核苷组合。